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ABSTRACT
Background. In the follow-up of papillary thyroid cancer
(PTC) patients treated with curative thyroidectomy and
radioiodine ablation, raised thyroglobulin (Tg) predicts
recurrence with reasonable sensitivity and specificity.
However, a proportion of patients present with raised Tg
level but no other clinical evidence of disease. Only limited
data on Tg kinetics have been reported to date. Here we
aim to evaluate the prognostic and predictive significance
of nonstimulated serum Tg velocity (TgV).
Methods. Consecutive PTC patients treated with curative
thyroidectomy and radioiodine ablation between 2003 and
2010 were analyzed. Patients with at least one detectable
Tg measurement ([0.2 ng/mL) were included. TgV was
defined as the annualized rate of Tg change. Logistic
regression analyses were performed to evaluate the role of
TgV in the prediction of disease recurrence. The optimal
TgV cutoff was assigned by receiver–operating character-
istic curve analysis. Overall survival of patients above
versus below the TgV cutoff were determined by the
Kaplan–Meier method and compared.
Results. Of a total of 501 patients, 87 had at least one Tg
value [0.2 ng/mL; in these latter patients, 29 (33.3 %)
developed recurrence. TgV was an independent predictor
of the recurrence. TgV C0.3 ng/mL per year predicted
recurrence with a sensitivity of 83.3 % and specificity of
94.4 %. Patients with TgV below the cutoff had a signifi-
cantly better overall survival (p = 0.038).
Conclusions. TgV predicts recurrence with high sensitiv-
ity and specificity, and is a prognosticator of survival in
postthyroidectomy and postablation PTC patients with
raised Tg.
In papillary thyroid cancer (PTC), thyroidectomy, radi-
oiodine (131I) therapy, and thyroid hormone suppression
are the mainstay of treatment, conferring excellent overall
survival.1 Despite effective initial treatment, the prognosis
is significantly affected by tumor recurrence, which occurs
in up to 30 % of patients at 30 years.2 Improvement of
current methods to detect recurrence early and accurately is
therefore clinically important.
Thyroglobulin (Tg) is a glycoprotein specific to differ-
entiated thyroid tissue; after thyroidectomy and radioiodine
remnant ablation, an elevated serum Tg level is a sensitive
marker of residual cancer.3 Periodical measurement of Tg
after initial thyroid ablative therapy is recommended in the
monitoring of PTC patients.4 Nevertheless, Tg level may
be affected by the various laboratory assays used.5 Inter-
ference may also occur in the presence of anti-Tg
antibodies or heterophile antibodies.6,7
The sensitivity of Tg can be increased with thyroid-
stimulating hormone (TSH) stimulated by either thyroid
hormone withdrawal or recombinant human TSH
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administration.8,9 On the other hand, some patients may
present with elevated interference-corrected Tg levels
alone, without clinical or radiological evidence of disease
at physical examination, neck ultrasound, diagnostic radi-
oiodine whole body scan (WBS), and/or computed
tomography (CT) or 18F-fluorodeoxyglucose–positron
emission tomography (FDG-PET). Although possibly
nonspecific especially with the development of increas-
ingly sensitive Tg assays, this condition is generally taken
to represent occult malignant disease.10,11 Empirical 131I
treatment is generally recommended at a Tg level of
5 ng/mL during or 10 ng/mL off thyroxine treatment.4,12
However, its clinical significance and management options
are in fact controversial based on the current literature.
Empirical radioiodine treatment has not been demonstrated
prospectively to be associated with improved outcome,
while in a retrospective study the majority of patients with
positive Tg and negative WBS remained free of disease at
8 years’ follow-up.13 Moreover, it has been postulated that
benign radioresistant ectopic thyroid or thymus tissue may
instead be the source of Tg secretion.3
In these patients, monitoring the Tg trend plays a par-
ticular role, but only limited evidence on the prognostic
and predictive significance of postablation Tg kinetics has
been reported to date. In the present study, we aimed to
evaluate the rate of change of nonstimulated serum Tg, or
Tg velocity (denoted by TgV), to predict recurrence in
postthyroidectomy and postablation PTC patients who have
raised Tg levels.
MATERIALS AND METHODS
Patients
Consecutive PTC patients undergoing primary thyroid-
ectomy with a curative intent in a tertiary referral center
between 2003 and 2010 were analyzed. Owing to the
adoption of different and less sensitive biochemical assays
before 2003, patients who presented before this date were
excluded. Patients with pathologies other than PTC,
including follicular carcinoma, Hu¨rthle cell carcinoma,
medullary carcinoma, anaplastic carcinoma, and lym-
phoma, were also excluded. All patients underwent total
thyroidectomy and neck dissection as required, with post-
operative radioiodine of 3 GBq administered to ablate
thyroid remnant. External-beam radiotherapy was consid-
ered in patients aged 45 or older with extrathyroidal tumor
extension, according to current guidelines.4 Postablation
WBS was performed subsequently; patients with residual
or metastatic disease were further excluded.
According to specified protocols as previously descri-
bed, nonstimulated serum Tg levels, TSH and free T4 were
measured and physical examination performed 3 months
after surgery and thereafter at each follow-up visit every
6 months, more frequently in patients with suspected
relapse.14 Tg values with a simultaneous raised TSH level
were excluded. Patients with at least one detectable Tg
measurement ([0.2 ng/mL) were included in the present
study; they were followed up for clinical outcomes of
recurrence and survival. Patients were included irrespective
of their anti-Tg antibodies, as Tg was evaluated longitu-
dinally rather than on the basis of individual measurements.
Ultrasonography of the neck was performed once every
6–12 months and chest X-ray annually, while other imag-
ing studies including WBS, CT, or FDG-PET were
performed upon clinical indication. In this study, recur-
rence was defined as the first relapse of disease detected on
imaging, and/or histological proof where clinically
feasible.
Biochemical Assays
Tg and TSH was determined by Immunite immunoassay
(Siemens Healthcare Diagnostics) and Advia Centaur TSH-
3 ultra chemiluminescent immunoassay (Siemens Health-
care Diagnostics), with sensitivities of 0.2 ng/mL and 0.03
mIU/L, respectively. Anti-Tg antibodies were detected by
Quanta Lite enzyme-linked immunosorbent assay (Inova
Diagnostics).
Definition of TgV
The first Tg value of [0.2 ng/mL noted during the
course of follow-up was denoted by Tg1, and the two
consecutive Tg values immediately after the first raised
value by Tg2 and Tg3. TgV was defined as the annualized
rate of Tg change. Two sets of TgV were determined in the
current study. Primary TgV (TgVp) was calculated by
[(Tg2 - Tg1)/(time elapsed in years)]. In addition, cumu-
lative TgV (TgVc) was determined by the summation of
[(Tg2 - Tg1)/(time elapsed in years)] and [(Tg3 - Tg2)/
(time elapsed in years)], to investigate any improvement in
sensitivity and specificity when the further trend of Tg
change was taken into account.
Statistical Analyses
Univariate and multivariate logistic regression analyses
were performed to evaluate the role of TgV among other
independent factors, including age, gender, primary tumor
and regional lymph node stage, and extrathyroid invasion,
in the prediction of disease recurrence. Moreover, the
optimal TgV cutoff for clinical purpose was determined by
receiver–operating characteristics (ROC) curve analysis.
Recurrence-free survival and overall survival of patients
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above versus below the TgV cutoff were determined by the
Kaplan–Meier method and compared by the log-rank test.
Statistical analyses were performed by the statistical soft-
ware SPSS Statistics, version 19. Significance was assumed
at p \ 0.05.
RESULTS
Patient Demographics
A total of 501 PTC patients underwent curative surgery
during the study period (Fig. 1). As a result of lack of
indications, presence of contraindications, or patient pref-
erence, 146 patients (29.1 %) did not receive postoperative
radioiodine ablation, while 10 (0.02 %) were found to have
residual or metastatic disease on postablation WBS; these
patients were excluded from further analysis. Tg kinetics
were evaluated in the remaining 345 patients, among whom
258 had undetectable Tg levels throughout the course of
their follow-up, while 87 had at least one Tg measurement
of[0.2 ng/mL. Of these latter patients, the median interval
between surgery and first raised Tg values was
13.3 months; 29 (33.3 %) developed recurrence, whereas
58 (66.7 %) showed no clinical or radiological evidence of
disease. The demographics of these patients are shown in
Table 1.
In the recurrent and disease-free patients, the median
ages at diagnosis were, respectively, 54 and 47 years; most
patients were female in both groups, consistent with local
epidemiology. Neck dissection and postoperative external-
beam radiotherapy were more frequently performed in the
recurrent group, although the difference did not reach
statistical significance. In these patients, however, more
often the primary tumor was 4 cm or larger or invaded
beyond the thyroid (i.e., stages T3–4 according to the
PTC patients
undergoing thyroidectomy
(n = 501)
At least one
detectable Tg
measurement
on follow up
(n = 87)
No residual disease on
post-ablation WBS
(n = 345)
Residual/metastatic disease
on post-ablation WBS
(n = 10)
Radioiodine ablation given
(n = 355)
Radioiodine ablation
not given
(n = 146)
Undetectable
Tg level
throughout
follow up
(n = 258)
Recurrent
disease
(n = 29)
No recurrent
disease
(n = 58)
FIG. 1 Patients undergoing thyroidectomy, radioiodine ablation, and
subsequent follow-up
TABLE 1 Demographics of patients with raised Tg levels after
operation and radioiodine ablation treatmenta
Characteristic Recurrent disease No disease p
value
Age, median (range) 54 (16–84) 47 (20–85) 0.320b
\45 years 10 (34.5) 26 (44.8)
C45 years 19 (65.5) 32 (55.2)
Gender 0.321
Male 10 (34.5) 14 (24.1)
Female 19 (65.5) 44 (75.9)
Neck dissection 0.219c
Not performed 6 (20.7) 20 (34.5)
Performed 21 (72.4) 35 (60.3)
Unilateral 16 (55.2) 15 (25.9)
Bilateral 3 (10.3) 5 (8.6)
Central 2 (6.9) 15 (25.9)
Postoperative external-
beam radiotherapy
0.077c
Not provided 23 (79.3) 54 (93.1)
Provided 6 (20.7) 4 (6.9)
Primary tumor (T)
stage
0.003c
T1–2 3 (10.3) 28 (48.3)
T3–4 23 (79.3) 27 (46.6)
Regional node (N)
stage
0.006c
N0–1a 8 (27.6) 29 (50.0)
N1b 15 (51.7) 17 (29.3)
MACIS score, median
(range)
5.97 (3.70–11.00) 5.05 (1.45–7.75) 0.011b
\6 13 (44.8) 36 (62.1)
6–6.99 3 (10.3) 8 (13.8)
7–7.99 4 (13.8) 10 (17.2)
C8 5 (17.2) 0 (0)
Total no. of patients 29 58
MACIS metastases, age, completeness of surgery, invasion, and size
a Data are presented as median (range) or n (%)
b Mann-Whitney U test
c Fisher’s exact test
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American Joint Committee on Cancer tumor, node,
metastasis staging system, 6th edition), and lymph node
staging was more advanced (p = 0.003 and 0.006,
respectively).15 Correspondingly, the MACIS (metastases,
age, completeness of surgery, invasion, and size) score was
significantly higher (p = 0.011).16
In the recurrent group, 18 patients (62.1 %) had disease
in the neck, 1 (3.4 %) in the tumor bed, and 7 (24.1 %) in
distant sites as the first site or sites of recurrence. As
treatment of recurrent disease, 18 patients (62.1 %)
underwent surgical resection, 23 (79.3 %) received further
radioiodine, 2 (6.9 %) received external-beam radiother-
apy, and 1 (3.4 %) was treated conservatively.
Univariate and Multivariate Logistic Regression
Analyses
On univariate analysis, classical clinicopathological
variables, including the presence of extrathyroidal exten-
sion (p = 0.006), higher primary tumor stage T3–4 vs.
T1–2 (p = 0.001), regional lymph node stage N2 vs.
N0–1a (p = 0.002), and higher TgV (p \ 0.0005), but not
age (p = 0.109) or gender (p = 0.157), were significantly
associated with recurrence. Multivariate logistic regression
produced a model, as presented in Table 2. However, only
TgV remained as an independent predictor of the recur-
rence outcome (odds ratio 1.140, 95 % confidence interval
1.024–1.269, p = 0.017).
TgV Kinetics
The median time between Tg1 and Tg2 measurement
and between Tg2 and Tg3 measurement were, respectively,
5.7 months (range 1.0–28.8 months) and 6.3 months
(range 1.3–19.9 months). Baseline Tg1 was significantly
higher in the recurrent compared to disease-free patients,
while confounding TSH levels were similar (Table 3).
TgVp (primary TgV, defined by [(Tg2 - Tg1)/(time
elapsed in years)]) was higher in the recurrent group
(Table 3). According to ROC analysis (Fig. 2), TgVp equal
to or greater than a cutoff value of 0.3 ng/mL per year was
found to predict recurrence with a sensitivity of 83.3 % and
a specificity of 94.4 %. The sensitivity of TgV could be
improved by determining TgVc (cumulative TgV, sum-
mation of [(Tg2 - Tg1)/(time elapsed in years)] and
[(Tg3 - Tg2)/(time elapsed in years)]). TgVc C0.6 mg/
mL per year predicted recurrence with a higher sensitivity
of 92.3 %, while specificity remained similar at 94.4 %.
Survival Outcomes and Recurrence Patterns
At a median follow-up of 56.8 months, the median
survival has not been reached. The Kaplan–Meier survival
curves are shown in Fig. 3. Preliminarily, patients with
TgVp \0.3 ng/mL per year had a significantly better
overall survival than those with TgVp at or above the
cutoff value (p = 0.038). In addition, all distant recurrence
occurred in patients with TgVp above the cutoff value.
TABLE 2 Logistic regression model of various independent vari-
ables in the prediction of recurrence
Variable B p value OR 95 % CI for OR
Upper Lower
TgVp 0.131 0.017 1.140 1.024 1.269
Extrathyroid invasion 0.668 0.508 1.950 0.270 14.085
Primary tumor stage T3–4 0.573 0.602 1.773 0.206 15.258
Regional node stage N1b 0.784 0.279 2.190 0.530 9.046
OR odds ratio, CI confidence interval
TABLE 3 Comparison of baseline Tg1, simultaneous TSH values,
and TgVp in patients with and without recurrent diseasea
Characteristic Recurrent disease No recurrence p
valueb
Tg1 7.25 (0.3 to 4800.0) 1.25 (0.3 to 117.0) \0.005
Simultaneous
TSH
With Tg1 0.03 (0.03 to 3.70) 0.06 (0.03 to 5.00) 0.064
With Tg2 0.03 (0.03 to 4.00) 0.03 (0.03 to 3.50) 0.810
With Tg3 0.03 (0.03 to 2.00) 0.03 (0.03 to 4.00) 0.283
TgVp 16.03 (-29.20 to
5383.75)
-0.67 (-27.31 to
6.80)
\0.005
Total no. of
patients
29 58
a Data are presented as median (range)
b Mann–Whitney U test
1.0
0.8
0.6
0.4
0.2
TgVp
TgVc
Reference line
1.00.0
1 - Specificity
Sensitivity
0.80.60.40.2
FIG. 2 Receiver–operating characteristics (ROC) curve of primary
TgV (TgVp) and cumulative TgV (TgVc)
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DISCUSSION
To our knowledge, the current study is the first in the liter-
ature to report the specific cutoff of TgV at 0.3 ng/mL per year
to predict recurrence, especially distant relapse, in postopera-
tive postablation PTC patients. More importantly, we have
demonstrated the prognostic role of such cutoff to predict sig-
nificantly different recurrence-free and overall survival.
The development of increasingly sensitive Tg assays has
improved the rate of disease detection while patients are
maintained on thyroxine therapy; it has been suggested that
these assays reduce the need for TSH stimulation.17 On the
other hand, test specificity may be compromised, leading to
more false-positive results. While receiving thyroxine,
Tg assays with functional sensitivities of 0.2–0.3 ng/mL
have a sensitivity and specificity of 54–63 % and
89 %, respectively, while assays with lower sensitivities of
0.02–0.1 ng/mL are associated with better sensitivity of
78–81 % but reduced specificity of 42–63 %.18 More
recently, ultrasensitive assays were reported to give a
sensitivity and specificity of 82.3% and 85.5–86.1 %,
respectively.17 In our study, TgV to detect recurrence was
shown to compare favorably with the above methods.
Furthermore, our findings are in principle concordant
with the limited evidence available on Tg kinetics. Baudin
et al.19 first confirmed the logical hypothesis that increasing
Tg levels on repeated measurements indicated recurrence.
This was a small study involving only 37 patients with Tg
measured after thyroxine withdrawal. Another study veri-
fied the observation that rising Tg, with TSH either
suppressed or stimulated, was associated with recurrence.20
In both of these studies, however, the rate of Tg rise above
which recurrence could be reliably predicted was not
reported. More recently, Miyauchi et al.21 showed that Tg
doubling time less than one year significantly predicted
locoregional recurrence and distant metastases. This study
was, however, designed with excessively stringent inclu-
sion criteria, excluding Tg samples taken with serum TSH
C0.1 mIU/L. It should be noted that data are lacking
regarding the appropriate level of serum TSH for evalua-
tion of Tg change, and that TSH suppression to below
0.1 mIU/L in all patients is contrary to current guide-
lines which instead recommend a range from \0.1 to
0.1–0.5 mIU/L to normal depending on individual risk.4
Patients with anti-Tg antibodies, defined by using cutoff
values set for Hashimoto thyroiditis, were also excluded;
the diagnostic cutoff level for anti-Tg antibodies in Tg
kinetic studies and whether these patients should be
excluded in such studies are not clear. Moreover, the cal-
culation of Tg doubling time in the study required at least 4
serial measurements, necessitating prolonged follow-up
before prognosis could be determined. All these factors
limited the clinical application of the study results. In our
study, on the other hand, Tg samples with simultaneous
TSH within or lower than the reference range, irrespective
of anti-Tg antibody status, were included. TgV was cal-
culated on the basis of 2–3 serial Tg measurements
6 months apart, allowing accurate recurrence prediction
over a minimal time interval.
Regarding its prognostic ability, Tg value measured at
a single time point did not correlate significantly with sur-
vival.22,23 However, the trend of Tg on serial measurements
was shown to predict survival in the current and previous
studies.21
TgV may therefore reflect disease aggressiveness. In
patients with rising Tg but no other clinical evidence of
disease, given that a TgV value above the cutoff predicted
recurrence, especially metastases, its potential role to guide
1.0
0.8
0.6
0.4
0.2
log rank p < 0.0005
1200
Recurrence free survival (months)
a
Cumulative
survival
20 40 60 80 100
1.0
0.8
0.6
0.4
0.2
log rank p = 0.038
1250
Overall survival (months)
b
Cumulative
survival
25 50 75 100
FIG. 3 Kaplan–Meier survival
curves according to TgVp cutoff
of 0.3 ng/mL per year. a
Recurrence-free survival. b
Overall survival
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the administration of radioiodine or novel molecular tar-
geted agents could be evaluated in future studies. On the
other hand, among the patients with recurrent disease, TgV
was below the proposed cutoff in 5 (17.2 %), including 3
(10.3 %) with a negative TgV signifying progressively
declining Tg levels. This observation is reflected in the
imperfect sensitivity and specificity associated with the
cutoff, and it highlights the importance of supplementary
clinical and radiological examinations in the follow-up of
PTC patients.
The current study has a few limitations. First, the ana-
lyzed sample size was modest. The median follow-up time
was also relatively short, considering the natural history of
thyroid cancer, where recurrence can occur decades after
treatment. The low recurrence rate in PTC renders patient
recruitment difficult; we chose to exclude patients treated
before the year 2003 in order to ensure a homogeneous study
population where the same Tg and TSH assays and scans
were used. Patients with undetectable Tg levels throughout
follow-up were excluded from analysis, leading to potential
selection bias in the complete evaluation of sensitivity and
specificity profile of TgV. Moreover, patients with raised Tg
were at times investigated with imaging earlier than speci-
fied in the follow-up protocol (Supplementary Table 1); this
might result in earlier detection of recurrence compared to
patients with undetectable Tg levels. However, these are less
likely to be significant pitfalls in the current study because
we analyzed only patients with raised Tg.
Our results are yet to be validated in a separate cohort.
Whether clinical outcome can be improved when treatment
decision is based on TgV has not been addressed. Finally,
the role of TgV in patients with subtotal thyroidectomy, in
those without radioiodine ablation, and in those with
metastatic disease should be investigated in further studies.
In conclusion, TgV predicts recurrence with high sen-
sitivity and specificity, and it is a prognosticator of survival
in postthyroidectomy and postablation PTC patients with
detectable Tg. Determination of TgV is simple and clini-
cally applicable, while avoiding adverse effects and patient
inconvenience associated with TSH stimulation. However,
further studies are necessary to validate our results, and
supplementary clinical and radiological examinations
remain essential in the follow of up PTC patients.
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